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Objective. A prospective follow-up study of patients with arterial restenosis undergoing cryoplasty.
Materials & methods. Between May 2004 and June 2005, 10 patients with restenosis following ilio-femoral endovascular
treatment underwent twelve cryoplasty procedures. All patients had had at least one previous episode of stenosis treated by
conventional endovascular methods and had suffered further restenosis. The indications for treatment were grafts at risk
(n¼ 5) and symptomatic in-stent restenosis (n¼ 5). Two patients underwent re-cryoplasty. Cryoplasty was performed in
accordance with manufacturer’s instructions using 6-8mm balloons. All patients had Doppler ultrasound evaluation at 1,
3, 6 and 12 months.
Results. All procedures had angiographically successful immediate outcome with <30% residual stenosis. Non flow lim-
iting dissection was evident in two cases. In six procedures (50%), restenosis was evident within 6 months post-procedure,
whilst in the other six, there was progressive restenosis appearing between 6e12 months. Five cryoplasty procedures have
needed endovascular re-intervention due to symptomatic high-grade restenosis and a sixth is awaiting surgery.
Conclusion. Cryoplasty is of no value in patients with restenosis in the iliofemoral segment with half the procedures fail-
ing within six months and all of them within the first year. Evidence to support the use of cryoplasty in the peripheral
arterial restenotic lesions is lacking.
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Percutaneous transluminal angioplasty (PTA) is well-
established as one of the initial management modalities
in peripheral arterial disease. The Achilles’ heel of PTA
is restenosis, which occurs in 30% to 80% of cases.1,2 The
reported 5-year success rate following iliac angioplasty
for stenosis is 53.4%3 and for femoro-popliteal disease,
the 1-month patency rate is 88.8% falling to 35.7% at
6 years. Distal run-off is an important factor in deter-
mining long-term patency with a success rate of 53%
at 5-years in cases with good run-off and 31% in
those with poor run-off.4 Factors such as Rutherford
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run-off also have all been shown to influence technical
success and long term patency.
Restenosis occurs due to elastic recoil, neointimal
hyperplasia (NIH), vessel remodelling, dissection of
the treated vessel, residual atherosclerotic burden at
the site of intervention, and progression of atheroscle-
rosis. NIH is caused by platelet activation at the site of
the arterial injury followed by migration and prolifer-
ation of smooth muscle cells. Various strategies have
been devised to prevent it. Kataoka et al. recently pro-
posed controlled freezing, or cryotherapy.5 As cryo-
plasty is believed to induce cellular apoptosis thus
preventing neo-intimal hyperplasia, we hypothesised
that it is likely to be of benefit in patients with arterial
restenosis following previous interventions. Although
principally being proposed as a primary treatment for
ilio-femoral stenoses, we have used it in this study in
patients whose previous history indicates that they
are NIH formers and at high risk of restenosis follow-
ing conventional angioplasty. We prospectivelyrved.
41Cryoplasty for Arterial Restenosisfollowed up a series of such patients who under went
cryoplasty over a 14-month period.
Materials and Methods
Ten patients underwent twelve cryoplasty proce-
dures over a 14-month period between May 2004
and June 2005. The mean age was 58.9 years (age
range e 49e72 years). Patient demographics and
risk factors are presented in Table 1.
All these patients had undergone at least one previ-
ous interventional procedure for revascularization
(Range of number of procedures prior to cryoplasty
was 1e4; mediane 2) (Tables 2a, 2b). Half of them
had previous surgical interventions. All were taking
life long antiplatelet agents. The indications for cryo-
plasty were graft at risk in 5 cases and instent resteno-
sis in the other five. Two patients went on to have
a repeat cryoplasty after the first procedure failed.
All patients were symptomatic with either intermit-
tent claudication or critical limb ischaemia. Approval
from the hospital ethics committee was obtained
prospectively.
All patients underwent duplex scanning of the
lower extremity arterial tree to ascertain the site,
extent and nature of lesion, and any other co-existing
lesions. An angiogram was performed immediately
pre-procedure to confirm duplex findings and also
assess the distal run-off. Measurement of arterial diam-
eter was used to decide on cryoplasty balloon size to
a maximum of 8 mm. Immediate post-procedure angi-
ography was performed to establish the success of the
procedure, improvement in the target lesion and to
look for complications. This was followed by periodic
follow-up duplex scans at one, three, six and twelve
months to assess the state of the repair or whenever
clinically indicated. At these times, patients were also
assessed for any evidence of return of symptoms or
change in the state of the affected limb. Any need for
repeat procedures was also noted.
Table 1. Patient demographics
Age range (in years) 49e72
Mean age (in years) 58.9
Gender (Male:Female) 6:4
Diabetes mellitus (%) 20
Hypercholesterolaemia (%) 100
Hypertension (%) 70
Current smokers (%) 40
Ex-smokers (%) 50
Coronary artery disease (%) 20
Family history of peripheral artery disease (%) 20
Number of previous interventions/patient (range) 1e4Cryoplasty was carried out using the PolarCath
(Boston Scientific, USA) system. This system includes
a cryoplasty catheter, a microprocessor-based inflation
unit and a nitrous oxide cylinder. All the guidelines
laid out for use of PolarCath were followed. Cryoplasty
essentially combines the traditional dilatation of the ste-
notic site using a transluminal balloon with simulta-
neous cold injury to the site of disease by delivering
liquid nitrous oxide at a temperature of 10 C. Liquid
nitrous oxide is the inflation medium used instead of
a standard mixture of saline and contrast medium. As
the liquid nitrous oxide enters the balloon, it undergoes
a phase shift to a gaseous form, which in turn causes ex-
pansion of the balloon. The treatment cycle of simulta-
neous dilatation and cooling lasts for 20 seconds. This
cycle is timed by the device and removes intra-operator
variation in treatment duration.
Following the procedure, patients were kept in hos-
pital for 24 hours and then discharged. All patients
were prescribed clopidogrel 300 mg/day for six weeks
and life-long aspirin 75 mg/day as is our standard
practice post PTA/stenting.
Duplex assessment involved direct insonation of
the treatment site with a focal doubling in peak
systolic velocity taken to indicate a 50% stenosis. All
patients who were detected to have restenosis were
then referred for further angiographic assessment
and intervention as indicated.
Results
Ten patients underwent twelve procedures over a four-
teen month period. Initial technical success, defined as
a residual stenosis of<30% and/or less than a grade C
dissection,6 was obtained in all twelve procedures
(100%). Two patients had a minor dissection (less
than grade C dissection) requiring no further treat-
ment. There were no other initial complications.
All 10 patients went on to develop significant reste-
nosis during follow-up at a mean duration of 6.2
months (range 1e12 months) post initial intervention.
Seven patients developed recurrence of short dis-
tance, lifestyle-limiting claudication following the
intervention and significant restenosis on the follow-
up arterial Doppler study. Six of these patients were
referred for further interventions, whilst the seventh
is under observation as his symptoms are relatively
mild after lifestyle modifications. Of the six patients
needing re-interventions, two patients have under-
gone repeat PTA and are currently of follow-up.
Two others had a repeat cryoplasty procedure within
6 months of the original procedure. Unfortunately,
both these had further symptomatic recurrence andEur J Vasc Endovasc Surg Vol 33, January 2007
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Prior interventions Site of current lesion Indication
Patient 1 PTA; stenting Right iliac artery Instent restenosis
Patient 2 Aorto-bifemoral grafting Right superficial femoral artery Graft at risk
Patient 3 Stenting Left iliac artery Instent restenosis
Patient 4 Stenting Left iliac artery Instent restenosis
Patient 5 Bilateral femoro-popliteal grafts; right graft stenting Right femoropopliteal graft Graft at risk
Patient 6 Right aortofemoral graft; PTA Right aortofemoral graft Graft at risk
Patient 7 Bilateral iliac stents Right iliac artery Instent restenosis
Patient 8 Aorto-bifemoral graft; bilateral PTA Left femoral artery Graft at risk
Patient 9 Stenting Right iliac artery Instent restenosis
Patient 10 Right femoro-popliteal grafting; PTA Right femoropopliteal graft Graft at riskrequired further conventional angioplasty 8 and 10
months after the second cryoplasty. At early follow
up both of these patients are asymptomatic. The fifth
patient has had brachytherapy and the sixth one is
awaiting surgery.
Two patients remain asymptomatic although
follow-up arterial Doppler assessment suggests sig-
nificant restenosis. They are both under surveillance
with regular clinical and Doppler assessment. Despite
failure of cryoplasty in the one remaining patient, she
has pain which is different from her presenting com-
plaint and which after evaluation is thought to be neu-
rogenic in origin. The patient awaits a complete
neurological evaluation.
Discussion
The vascular repair process following balloon dilata-
tion injury of vessel and/or stent implantation is an
aggressive process of platelet activation leading to
smooth muscle migration and proliferation resulting
in exuberant neointimal formation.7,8 It may reflect
a healthy healing process but it ultimately leads to
Table 2b. Patients’ follow-up after initial cryoplasty
Duration
of freedom
from
restenosis
(months)
Return of
symptoms
Reintervention
Patient 1 12 Yes Brachytherapy
Patient 2 5 Yes Recryoplasty
failed; cutting
PTA
Patient 3 7 No No; on follow-up
Patient 4 3 Yes No; on follow-up
Patient 5 12 Yes Awaiting redo
surgery
Patient 6 6 Yes Recryoplasty
failed; Re-PTA
Patient 7 6 Yes Re-PTA
Patient 8 1 Yes Re-PTA cutting
Patient 9 6 ?Neurogenic
pain
Neurology
referral
Patient 10 4 No No; on follow-upEur J Vasc Endovasc Surg Vol 33, January 2007restenosis. Since stenting reduced the additional prob-
lem of recoil, most strategies attempting to overcome
the problem of restenosis have targeted NIH forma-
tion. These include brachytherapy, heat stress, ultra-
sound photodynamic therapy and local delivery of
cellular suppressants using drug-eluting stents.5
However, none of these have been particularly suc-
cessful. Cryoplasty has been developed as a new tech-
nique for limiting NIH by inducing cellular apoptosis
in smooth muscle cells.
Grassl et al. demonstrated that freezing destroys
smooth muscle cells.9 Smooth muscle migration and
proliferation along with formation of extracellular
collagen matrix is central to neointimal hyperplasia.
However, this study also showed that certain smooth
muscle cell groups were less sensitive to the freezing
effect in differing conditions and whilst encouraging
results were obtained, a clear need for further re-
search in this direction was identified. It is most likely
that it is these cellular populations that make some
patients more prone to arterial restenosis and also
why success in the coronary arteries does not neces-
sarily translate to success in ilio-femoral disease.
Two recent studies have demonstrated favourable
results of cryoplasty in the management of lower
limb arterial lesions. Fava et al. studied the effect of cry-
oplasty in 15 patients with varying grades of de-novo
stenotic or occlusive lesions of the femoro-popliteal
system. The procedure was technically successful in
93% of the patients. Two of the patients developed
complications remote from the cryoplasty site necessi-
tating stenting. Late angiographic follow-up at a mean
of 14 months demonstrated a primary patency rate of
83.3% among 9 patients out of the original study group
of 15.10
A recently published prospective multicentre regis-
try has also suggested a high degree of angiographic
success with cryoplasty compared with other tech-
niques.11 This study reported on 102 patients with
intermittent claudication of the lower extremity with
TASC A-C (TransAtlantic Inter-Society Consensus) Pa-
tients with recent myocardial infarction or stroke and
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excluded. They also excluded patients with instent
restenosis, rest pain and ischaemic foot ulcers. Ninety
patients completed the follow-up. Of these, only 77
follow-up duplex imaging scans were deemed by the
core laboratory to be of an adequate quality for inde-
pendent interpretation. The initial technical success
was achieved in 85.3%, with a 6.9% dissection rate.
Overall success rate was 94.1% (including ‘‘bailout’’
stent procedures). Amongst patients with total occlu-
sions, the success rate is 67%. For all patients, the 9-
month clinical and duplex scan patency rate is 82.2%
and 70.1% respectively. Although, the authors in-
cluded patients with both denovo (84.3%) and reste-
notic (15.7%) lesions, they have not analyzed the
restenotic group separately for both early and mid-
term results.
A further follow-up study by Laird et al. has dem-
onstrated a clinical patency rate of 83.2% at just over 9
months and 75% at 3 years in 70 patients from the
original study.12 This appears favourable when com-
pared with the primary standard PTA rates demon-
strated in a meta-analysis but is not statistically
robust. The combined 3-year patency rates for standard
PTA for femoropopliteal disease 61% for stenoses and
claudication, 48% for occlusions and claudication,
43% for stenoses and critical ischaemia, 30% for oc-
clusions and critical ischaemia. Muradin reported
63e66% for stent implantation regardless of clinical
indication or lesion type.13 However, despite excellent
results in denovo lesions, there is no further clarifica-
tion of the results of cryoplasty in the sub-group of
patients having restenotic lesions.
We have analysed the results of this technique in
a group of patients with significant restenotic or oc-
clusive lesions either following previous stenting or
angioplasty. We based this study on the results of
cryoplasty in animal studies which had shown
much promise in inhibiting NIH.9 Its cost-effective-
ness has not been assessed and is an issue as the stan-
dard PTA balloon catheter costs one tenth of the cost
of cryoplasty. (standard PTA catheter, £50; PolarCath,
£300; inflation cooling unit, £200). Hence the cost of
the procedure must be justified. In addition, cryo-
plasty requires an 8 Fr. puncture rather than a 4e6
Fr one.
In theory, cryoplasty should be of most benefit in
those patients who are recurrent NIH formers. This
study is limited by a small selective study group
and non-randomised retrospective nature. Unfortu-
nately, the results of cryoplasty in this highly select
group of patients are disappointing with half theprocedures failing within six months and all of them
within the first year.
This study would suggest that cryoplasty is un-
helpful in treating restenosis caused by recurrent
neo-intimal hyperplasia. Registry and cohort data is
unlikely to provide sufficient information regarding
cost effectiveness and can only reasonably be used
to prove safety. There is a need for a significantly
powered randomised study to demonstrate efficacy
and effectiveness in restenotic iliofemoral atheroscle-
rotic stenotic and occlusive disease.
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